Key Points
- Omeros CAO David Borges sold 30,000 shares on January 13 at an average price of $12.31, a transaction totaling $369,300, according to an SEC filing.
- The company beat last quarter's EPS estimate (reported -$0.19 vs. consensus -$0.58) but analysts expect Omeros to post about -$3.09 EPS for the current year; the stock trades around $13.08 with a 1-year range of $2.95–$17.65, a market cap of ~$927M and a beta of 2.38.
- Analyst views are mixed but the consensus rating is a "Moderate Buy" with an average target price of $40.33, and institutional investors hold roughly 48.8% of the shares with firms like Vanguard and Two Sigma recently increasing positions.
Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 30,000 shares of the firm's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Omeros Price Performance
NASDAQ:OMER opened at $13.08 on Thursday. Omeros Corporation has a 1-year low of $2.95 and a 1-year high of $17.65. The stock has a market cap of $927.37 million, a P/E ratio of -6.48 and a beta of 2.38. The firm has a 50-day moving average of $10.93 and a two-hundred day moving average of $6.86.
Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, equities analysts expect that Omeros Corporation will post -3.09 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on OMER shares. Weiss Ratings restated a "sell (d-)" rating on shares of Omeros in a research note on Wednesday, October 8th. WBB Securities reissued a "strong-buy" rating and issued a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen cut shares of Omeros from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Wednesday, October 15th. Finally, D. Boral Capital restated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.33.
View Our Latest Stock Report on OMER
Institutional Investors Weigh In On Omeros
Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Omeros by 1.9% during the third quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company's stock valued at $13,723,000 after purchasing an additional 63,381 shares during the last quarter. Two Sigma Investments LP increased its position in Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company's stock worth $3,827,000 after buying an additional 263,095 shares during the period. Marshall Wace LLP lifted its stake in Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock valued at $2,224,000 after buying an additional 97,224 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Omeros by 1.4% during the second quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company's stock valued at $1,713,000 after acquiring an additional 8,000 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company's stock worth $1,706,000 after acquiring an additional 384,168 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.
About Omeros
(
Get Free Report)
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
